The findings were similar in people with or without diabetes.
In a simulated evaluation, adding Farxiga (dapagliflozin) to guideline-directed medical therapy was projected to produce substantial clinical gains for patients with heart failure with reduced ejection fraction (HFrEF) with an acceptable increase in associated costs, according to a new study published July 27, 2021, on JAMA Network Open.
At a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) gained, treatment with Farxiga, at an assumed annual cost of $4,192, would be a cost-effective therapy in patients with HFrEF.
Farxiga was projected to add 0.63 QALYs at an incremental lifetime cost of $42,800, for an incremental cost-effectiveness ratio of $68,300 per QALY gained. Findings were similar in people with or without diabetes. Investigators found adding Farxiga was cost-effective in 94% of 10,000 probabilistic simulations, and they said this suggests that the findings are robust across a wide range of estimates of key model parameters.
In this analysis, investigators simulated a cohort of patients at least 66 years of age and with 41.8% who had diabetes at baseline. Median survival in the guideline-directed medical therapy arm was 6.8 years, with a range of 3.5 to 11.3 years.
Investigators’ primary outcome was incremental cost-effectiveness ratio of adding Farxiga to guideline-directed medical therapy compared with guideline-directed medical therapy for the entire cohort and stratified by baseline diabetes status.
Farxiga, developed by AstraZeneca, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor approved to treat patients with type 2 diabetes, heart failure, and in April 2021 for chronic kidney disease.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More